Using a chatbot to improve genetic risk assessment for hereditary cancer
Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population
NA · Weill Medical College of Cornell University · NCT05562778
This study is testing if a chatbot can help more patients at risk for hereditary cancer get recommended for genetic testing compared to regular care in a gynecology clinic.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University (other) |
| Locations | 4 sites (Brooklyn, New York and 3 other locations) |
| Trial ID | NCT05562778 on ClinicalTrials.gov |
What this trial studies
This study compares a mobile health platform, specifically a chatbot utilizing artificial intelligence and natural language processing, to standard care in a gynecology clinic. The goal is to determine if the chatbot can enhance the recommendation rates for genetic testing among patients at higher risk for hereditary cancer syndromes. Additionally, the study will assess barriers to access and utilization of genetic testing services among these patients. Participants must be 8 years or older, scheduled for a new patient appointment, and have not undergone prior genetic testing.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 8 years and older who are scheduled for a new patient appointment in a gynecology clinic and have not previously undergone genetic testing.
Not a fit: Patients who have already had genetic testing for hereditary cancer syndromes or are under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase the identification of patients who would benefit from genetic testing for hereditary cancer syndromes.
How similar studies have performed: While the use of chatbots in healthcare is emerging, this specific application for hereditary cancer risk assessment is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 8 years of age or older. * Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English. * Access to a telephone with texting capacity. * Has not had prior genetic testing for hereditary cancer syndromes. Exclusion Criteria: * Under 18 years of age * Has had previous genetic testing for hereditary cancer syndromes * Does not read/speak in English * Does not have access to a phone with texting capabilities
Where this trial is running
Brooklyn, New York and 3 other locations
- NYP Brooklyn Methodist Hospital — Brooklyn, New York, United States (RECRUITING)
- NYP Lower Manhattan Hospital — New York, New York, United States (RECRUITING)
- Weill Cornell Medicine — New York, New York, United States (RECRUITING)
- NYP Medical Group Queens — Queens, New York, United States (RECRUITING)
Study contacts
- Principal investigator: Melissa K Frey, MD — Weill Medical College of Cornell University
- Study coordinator: Melissa K Frey, MD, MS
- Email: mkf2002@med.cornell.edu
- Phone: 212-746-3049
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Gynecologic Cancer, Hereditary Cancer Syndrome